Lee's Pharmaceutical Kept Up the Rapid Pace of Growth; Profit Attributable to Shareholders Surged 176% in the Nine Mont...( HONG KONG Nov. 12 /Xinhua-- ...),Health

HONG KONG, Nov. 12 /Xinhua-PRNewswire/ --

Financial Review (For the 9 months ended 30 September)

Unaudited Consolidated Figures

2008 2007 Change

(HK$'000) (HK$'000) (%)

Turnover 89,760 51,486 +74%

Gross Profit 63,408 35,647 +78%

Profit Attributable to 20,702 7,499 +176%

shareholders

Earnings per Share

(Basic) HK4.99 cents HK2.15 cents +132%

Lee's Pharmaceutical Holdings Limited ("Lee's Pharmaceutical" or the "Group", HKEx: 8221), an integrated research-driven and market-oriented pharmaceutical group in China, today announced its third quarter results for the 9 months ended 30 September 2008 (the "period under review").

Lee's Pharmaceutical had kept up the rapid pace of growth in the third quarter with substantial increase in both revenue and profit. Revenue for the 9 months ended 30 September 2008 recorded HK$89.8 million, representing a 74% growth compared with the same period in 2007. The Group's profit attributable to shareholders surged to HK$8.3 million during the third quarter, as well as increased 176% to HK$ 20.7 million between January to September in 2008. The increase in revenue in the third quarter was mainly attributable to strong sales growth of the newly launched in-house product Slounase(R). The Group's major product -- Yallaferon(R) was a contributor to generate 60% more revenue growth over the same period last year. As a new income source, the sales of the newly launched license-in product Iron Proteinsuccinylate also experienced stable growth during the period under review, in line with the management's expectation.

The substantial growth in profitability of the Group could be attributed main
'/>"/>